| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2429 | 2019 |
| Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis WAME Schrijver, KPM Suijkerbuijk, CH Van Gils, E Van Der Wall, ... JNCI: Journal of the National Cancer Institute 110 (6), 568-580, 2018 | 265 | 2018 |
| Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis J Larkin, B Chmielowski, CD Lao, FS Hodi, W Sharfman, J Weber, ... The oncologist 22 (6), 709-718, 2017 | 258 | 2017 |
| Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ... New England journal of medicine 387 (23), 2113-2125, 2022 | 211 | 2022 |
| Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial ILM Reijers, AM Menzies, ACJ Van Akkooi, JM Versluis, ... Nature medicine 28 (6), 1178-1188, 2022 | 181 | 2022 |
| The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2α EH Gort, G Van Haaften, I Verlaan, AJ Groot, RHA Plasterk, A Shvarts, ... Oncogene 27 (11), 1501-1510, 2008 | 172 | 2008 |
| Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1–treated patients in the Dutch melanoma treatment registry RJ Verheijden, AM May, CU Blank, MJB Aarts, FWPJ van den Berkmortel, ... Clinical Cancer Research 26 (9), 2268-2274, 2020 | 135 | 2020 |
| Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer EH Gort, KPM Suijkerbuijk, SM Roothaan, V Raman, M Vooijs, ... Cancer Epidemiology Biomarkers & Prevention 17 (12), 3325-3330, 2008 | 123 | 2008 |
| Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations C Menzer, AM Menzies, MS Carlino, I Reijers, EJ Groen, T Eigentler, ... Journal of Clinical Oncology 37 (33), 3142-3151, 2019 | 105 | 2019 |
| Biomarkers of checkpoint inhibitor induced immune-related adverse events—a comprehensive review JW Hommes, RJ Verheijden, KPM Suijkerbuijk, D Hamann Frontiers in oncology 10, 585311, 2021 | 97 | 2021 |
| Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer KPM Suijkerbuijk, MJ Fackler, S Sukumar, CH van Gils, T van Laar, ... Annals of oncology 19 (11), 1870-1874, 2008 | 94 | 2008 |
| Dutch Oncology COVID-19 consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study K de Joode, DW Dumoulin, J Tol, HM Westgeest, LV Beerepoot, ... European Journal of Cancer 141, 171-184, 2020 | 82 | 2020 |
| First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO … CU Blank, ILM Reijers, T Pennington, JM Versluis, RPM Saw, ... Journal of Clinical Oncology 38 (15_suppl), 10002-10002, 2020 | 78 | 2020 |
| Improving early breast cancer detection: focus on methylation KPM Suijkerbuijk, PJ Van Diest, E Van der Wall Annals of Oncology 22 (1), 24-29, 2011 | 68 | 2011 |
| Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study MK van der Kooij, KPM Suijkerbuijk, MJB Aarts, FWPJ van den Berkmortel, ... Annals of internal medicine 174 (5), 641-648, 2021 | 63 | 2021 |
| Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition A Rogiers, IP Da Silva, C Tentori, CA Tondini, JM Grimes, MH Trager, ... Journal for ImmunoTherapy of Cancer 9 (1), 2021 | 61 | 2021 |
| Methylation profiles of hereditary and sporadic ovarian cancer GM Bol, KPM Suijkerbuijk, J Bart, M Vooijs, E Van Der Wall, PJ Van Diest Histopathology 57 (3), 363-370, 2010 | 60 | 2010 |
| Association of immune-related adverse event management with survival in patients with advanced melanoma OJ Van Not, RJ Verheijden, AJM Van Den Eertwegh, JBAG Haanen, ... JAMA oncology 8 (12), 1794-1801, 2022 | 46 | 2022 |
| Real‐world outcomes of advanced melanoma patients not represented in phase III trials MCT van Zeijl, RK Ismail, LC de Wreede, AJM van den Eertwegh, ... International journal of cancer 147 (12), 3461-3470, 2020 | 42 | 2020 |
| Physical activity in relation to mammographic density in the dutch prospect-European prospective investigation into cancer and nutrition cohort KPM Suijkerbuijk, FJB Van Duijnhoven, CH Van Gils, PAH Van Noord, ... Cancer Epidemiology Biomarkers & Prevention 15 (3), 456-460, 2006 | 39 | 2006 |
